AstraZeneca's Farxiga Drug For Type 2 Diabetes Cuts Heart-Related Complications

AstraZeneca's Farxiga Drug For Type 2 Diabetes Cuts Heart-Related Complications

In the interim, however, the pharma sponsored the CVD-REAL study, which pulled data from health claims, registries and other medical records to assess the outcomes of over 300,000 patients across six countries, including the USA and the United Kingdom.

More than 400 million people worldwide have diabetes, of whom at least 90 percent have type 2.

AstraZeneca PLC reported data from a significant study with its diabetes drug Farxiga, showing that the drug reduces hospitalisation for heart failure and death from patients with type-2 diabetes. Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalizations for heart failure and death by approximately half.

The analysis for hospitalization for heart failure was conducted on patient data from Denmark, Germany, Norway, Sweden, U.K. and the U.S., while the analysis for death from heart failure was conducted on patient data from Denmark, Norway, Sweden, U.K. and the U.S. Around 42% of the patients were on AstraZeneca's Farxiga, around 53% on JNJ's Invokana, and rest on Jardiance. That's why a 2015 study demonstrating that Lilly and Boehringer's Jardiance significantly reduced the risk of cardiovascular deaths generated excitement around the prospects of the SGLT-2 drugs. The heart benefit has since been incorporated into Jardiance's label.

The Empa-Reg Outcome reflected that Jardiance reduced cardiovascular deaths by 38 percent.

AstraZeneca is conducting its own large clinical trials to determine the heart effect of Farxiga with results expected in 2019.

"The fact that the results are remarkably consistent from country to country regardless of which compound predominates, that certainly seems to suggest that it's a class effect", said Kosiborod, a cardiologist from Saint Luke's Mid America Heart Institute in Kansas City.

Patients treated with Farxiga, Invokana or Jardiance were compared to those taking other medications for type 2 diabetes, such as insulins or DPP-4s. The data were presented at the American College of Cardiology 66th Annual Scientific Session. Most of the patients on SGLT-2s received either Farxiga or Invokana, while fewer than 10% of patients took Jardiance.